Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Kåresen R[au]:

Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. Aure MR et al. Breast Cancer Res. (2017)

Re: En varslet katastrofe. Kåresen R et al. Tidsskr Nor Laegeforen. (2017)

Using clinical cancer registry data for estimation of quality indicators: Results from the Norwegian breast cancer registry. Hartmann-Johnsen OJ et al. Int J Med Inform. (2019)

Search results

Items: 1 to 50 of 128

1.

Using clinical cancer registry data for estimation of quality indicators: Results from the Norwegian breast cancer registry.

Hartmann-Johnsen OJ, Kåresen R, Schlichting E, Naume B, Nygård JF.

Int J Med Inform. 2019 May;125:102-109. doi: 10.1016/j.ijmedinf.2019.03.004. Epub 2019 Mar 9.

3.

Re: En varslet katastrofe.

Kåresen R.

Tidsskr Nor Laegeforen. 2017 May 23;137(10):682. doi: 10.4045/tidsskr.17.0339. eCollection 2017 May. Norwegian. No abstract available.

PMID:
28551949
Free Article
4.

Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.

Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E, Sauer T, Mills GB, Kåresen R, Mælandsmo GM, Lingjærde OC, Frigessi A, Kristensen VN, Børresen-Dale AL, Sahlberg KK; OSBREAC.

Breast Cancer Res. 2017 Mar 29;19(1):44. doi: 10.1186/s13058-017-0812-y.

5.

En handlingens mann.

Kåresen R, Lunde C.

Tidsskr Nor Laegeforen. 2015 Dec 15;135(23-24):2148-50. doi: 10.4045/tidsskr.15.1176. eCollection 2015 Dec 15. Norwegian. No abstract available.

6.

The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer.

Silwal-Pandit L, Russnes H, Borgen E, Skarpeteig V, Moen Vollan HK, Schlichting E, Kåresen R, Naume B, Børresen-Dale AL, Farnebo M, Langerød A.

PLoS One. 2015 Oct 13;10(10):e0139965. doi: 10.1371/journal.pone.0139965. eCollection 2015.

7.

Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.

Tinholt M, Vollan HK, Sahlberg KK, Jernström S, Kaveh F, Lingjærde OC, Kåresen R, Sauer T, Kristensen V, Børresen-Dale AL, Sandset PM, Iversen N.

Breast Cancer Res. 2015 Mar 26;17:44. doi: 10.1186/s13058-015-0548-5.

8.

Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer.

Aure MR, Jernström S, Krohn M, Vollan HK, Due EU, Rødland E, Kåresen R; Oslo Breast Cancer Research Consortium (OSBREAC), Ram P, Lu Y, Mills GB, Sahlberg KK, Børresen-Dale AL, Lingjærde OC, Kristensen VN.

Genome Med. 2015 Feb 2;7(1):21. doi: 10.1186/s13073-015-0135-5. eCollection 2015.

9.

Survival is Better After Breast Conserving Therapy than Mastectomy for Early Stage Breast Cancer: A Registry-Based Follow-up Study of Norwegian Women Primary Operated Between 1998 and 2008.

Hartmann-Johnsen OJ, Kåresen R, Schlichting E, Nygård JF.

Ann Surg Oncol. 2015 Nov;22(12):3836-45. doi: 10.1245/s10434-015-4441-3. Epub 2015 Mar 6.

10.

Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study.

Tinholt M, Viken MK, Dahm AE, Vollan HK, Sahlberg KK, Garred O, Børresen-Dale AL, Jacobsen AF, Kristensen V, Bukholm I, Kåresen R, Schlichting E, Skretting G, Lie BA, Sandset PM, Iversen N.

BMC Cancer. 2014 Nov 19;14:845. doi: 10.1186/1471-2407-14-845.

11.
12.

[Breast cancer surgery in Norway 1986-2009].

Hofvind S, Schlichting E, Ursin G, Sebuødegård S, Kåresen R.

Tidsskr Nor Laegeforen. 2013 Aug 20;133(15):1582-6. doi: 10.4045/tidsskr.12.0840. Norwegian.

13.

Effects of a psychoeducational versus a support group intervention in patients with early-stage breast cancer: results of a randomized controlled trial.

Schou Bredal I, Kåresen R, Smeby NA, Espe R, Sørensen EM, Amundsen M, Aas H, Ekeberg Ø.

Cancer Nurs. 2014 May-Jun;37(3):198-207. doi: 10.1097/NCC.0b013e31829879a3.

PMID:
23782517
14.

Recall mammography and psychological distress.

Schou Bredal I, Kåresen R, Skaane P, Engelstad KS, Ekeberg Ø.

Eur J Cancer. 2013 Mar;49(4):805-11. doi: 10.1016/j.ejca.2012.09.001. Epub 2012 Sep 27.

PMID:
23021930
15.

Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy.

Synnestvedt M, Borgen E, Russnes HG, Kumar NT, Schlichting E, Giercksky KE, Kåresen R, Nesland JM, Naume B.

Acta Oncol. 2013 Jan;52(1):91-101. doi: 10.3109/0284186X.2012.713508. Epub 2012 Aug 30.

PMID:
22934555
17.
18.

Hospital volume and prognosis among Norwegian breast cancer patients enrolled in adjuvant trials.

Fjösne HE, Søreide JA, Kåresen R, Lønning PE, Jacobsen AB, Lundgren S; NORWEGIAN BREAST CANCER GROUP (NBCG).

Acta Oncol. 2011 Oct;50(7):1068-74. doi: 10.3109/0284186X.2011.585998. Epub 2011 Jul 11.

PMID:
21745131
20.

DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables.

Kamalakaran S, Varadan V, Giercksky Russnes HE, Levy D, Kendall J, Janevski A, Riggs M, Banerjee N, Synnestvedt M, Schlichting E, Kåresen R, Shama Prasada K, Rotti H, Rao R, Rao L, Eric Tang MH, Satyamoorthy K, Lucito R, Wigler M, Dimitrova N, Naume B, Borresen-Dale AL, Hicks JB.

Mol Oncol. 2011 Feb;5(1):77-92. doi: 10.1016/j.molonc.2010.11.002. Epub 2010 Dec 2.

21.

[Against organizational chaos?].

Kåresen R.

Tidsskr Nor Laegeforen. 2010 Dec 16;130(24):2453. doi: 10.4045/tidsskr.10.1284. Norwegian. No abstract available.

22.
23.

Prognostic value of health-related quality-of-life parameters in early-stage breast cancer: an 8-year follow-up study.

Bredal IS, Sandvik L, Karesen R, Ekeberg O.

Psychooncology. 2011 Oct;20(10):1102-7. doi: 10.1002/pon.1822. Epub 2010 Aug 25.

PMID:
20737644
24.

Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

Russnes HG, Vollan HKM, Lingjærde OC, Krasnitz A, Lundin P, Naume B, Sørlie T, Borgen E, Rye IH, Langerød A, Chin SF, Teschendorff AE, Stephens PJ, Månér S, Schlichting E, Baumbusch LO, Kåresen R, Stratton MP, Wigler M, Caldas C, Zetterberg A, Hicks J, Børresen-Dale AL.

Sci Transl Med. 2010 Jun 30;2(38):38ra47. doi: 10.1126/scitranslmed.3000611.

25.

[Survival after breast cancer--differences between Norwegian counties].

Kalager M, Kåresen R, Wist E.

Tidsskr Nor Laegeforen. 2009 Dec 17;129(24):2595-600. doi: 10.4045/tidsskr.09.0024. Norwegian.

26.

Changes in arm morbidities and health-related quality of life after breast cancer surgery - a five-year follow-up study.

Sagen A, Kåresen R, Sandvik L, Risberg MA.

Acta Oncol. 2009;48(8):1111-8. doi: 10.3109/02841860903061691.

PMID:
19863218
27.
28.

Validity for the simplified water displacement instrument to measure arm lymphedema as a result of breast cancer surgery.

Sagen A, Kåresen R, Skaane P, Risberg MA.

Arch Phys Med Rehabil. 2009 May;90(5):803-9. doi: 10.1016/j.apmr.2008.11.016.

PMID:
19406300
29.

The prognostic impact of occult nodal metastasis in early breast carcinoma.

Park D, Kåresen R, Naume B, Synnestvedt M, Beraki E, Sauer T.

Breast Cancer Res Treat. 2009 Nov;118(1):57-66. doi: 10.1007/s10549-009-0340-2. Epub 2009 Feb 15.

PMID:
19219629
30.

Psychosocial intervention as a component of routine breast cancer care-who participates and does it help?

Schou I, Ekeberg O, Karesen R, Sorensen E.

Psychooncology. 2008 Jul;17(7):716-20.

PMID:
18033695
31.

Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer.

Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Strømberg M, Wiedswang G, Kvalheim G, Kåresen R, Nesland JM, Børresen-Dale AL, Sørlie T.

Mol Oncol. 2007 Sep;1(2):160-71. doi: 10.1016/j.molonc.2007.03.004. Epub 2007 Apr 4. Erratum in: Mol Oncol. 2010 Apr;4(2):169.

32.

Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications.

Park D, Kåresen R, Noren T, Sauer T.

Virchows Arch. 2007 Jul;451(1):11-8. Epub 2007 Jun 7.

PMID:
17554555
33.

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.

Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL, Jeffrey SS.

Breast Cancer Res. 2007;9(3):R30.

35.

[Sentinel lymph node biopsy in breast cancer].

Schlichting E, Harr ME, Sauer T, Babovic A, Kåresen R.

Tidsskr Nor Laegeforen. 2006 Aug 24;126(16):2098-100. Norwegian.

36.

Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer.

Wiedswang G, Borgen E, Schirmer C, Kåresen R, Kvalheim G, Nesland JM, Naume B.

Int J Cancer. 2006 Apr 15;118(8):2013-9.

37.

[Breast cancer surgery in Norway].

Kåresen R.

Tidsskr Nor Laegeforen. 2005 Mar 3;125(5):555. Norwegian. No abstract available.

38.

Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications.

Kristensen VN, Sørlie T, Geisler J, Langerød A, Yoshimura N, Kåresen R, Harada N, Lønning PE, Børresen-Dale AL.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):878s-83s. Review.

39.

The reliability of a simplified water displacement instrument: a method for measuring arm volume.

Sagen A, Kåresen R, Risberg MA.

Arch Phys Med Rehabil. 2005 Jan;86(1):86-9.

PMID:
15640996
40.

Mutation of GATA3 in human breast tumors.

Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X, Langerød A, Kåresen R, Oh DS, Dressler LG, Lønning PE, Strausberg RL, Chanock S, Børresen-Dale AL, Perou CM.

Oncogene. 2004 Oct 7;23(46):7669-78.

PMID:
15361840
41.

Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome.

Wiedswang G, Borgen E, Kåresen R, Qvist H, Janbu J, Kvalheim G, Nesland JM, Naume B.

Clin Cancer Res. 2004 Aug 15;10(16):5342-8.

42.

Pessimism as a predictor of emotional morbidity one year following breast cancer surgery.

Schou I, Ekeberg Ø, Ruland CM, Sandvik L, Kåresen R.

Psychooncology. 2004 May;13(5):309-20.

PMID:
15133772
43.

The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells.

Naume B, Wiedswang G, Borgen E, Kvalheim G, Kåresen R, Qvist H, Janbu J, Harbitz T, Nesland JM.

Clin Cancer Res. 2004 May 1;10(9):3091-7.

44.

Different gene expression patterns in invasive lobular and ductal carcinomas of the breast.

Zhao H, Langerød A, Ji Y, Nowels KW, Nesland JM, Tibshirani R, Bukholm IK, Kåresen R, Botstein D, Børresen-Dale AL, Jeffrey SS.

Mol Biol Cell. 2004 Jun;15(6):2523-36. Epub 2004 Mar 19.

45.

Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer.

Yoshimura N, Harada N, Bukholm I, Kåresen R, Børresen-Dale AL, Kristensen VN.

Breast Cancer Res. 2004;6(2):R46-55. Epub 2003 Dec 11.

46.

Do women newly diagnosed with breast cancer and consulting surgeon assess decision-making equally?

Schou I, Ekeberg Ø, Ruland CM, Kåresen R.

Breast. 2002 Oct;11(5):434-41.

PMID:
14965708
47.

Micrometastasis to axillary lymph nodes and bone marrow in breast cancer patients.

Wiedswang G, Naess AB, Naume B, Kåresen R.

Breast. 2001 Jun;10(3):237-42.

PMID:
14965591
48.

Screening for breast cancer is associated with a low degree of psychological distress.

Ekeberg Ø, Skjauff H, Kåresen R.

Breast. 2001 Feb;10(1):20-4.

PMID:
14965553
49.

Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.

Wiedswang G, Borgen E, Kåresen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B.

J Clin Oncol. 2003 Sep 15;21(18):3469-78.

PMID:
12972522
50.

[Medical logistics: principles applied to diagnostics and therapy in women with symptoms and signs of breast cancer].

Kåresen R, Hervik A, Schlichting E.

Tidsskr Nor Laegeforen. 2003 Jun 12;123(12):1687-90. Norwegian.

PMID:
12821992

Supplemental Content

Loading ...
Support Center